trending Market Intelligence /marketintelligence/en/news-insights/trending/vkp2e900umb_9lvrvpx8bw2 content esgSubNav
In This List

ASCO conference: 70% with early breast cancer can skip chemo with Genomic's test

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: 70% with early breast cancer can skip chemo with Genomic's test

A study of Genomic Health Inc.'s breast cancer test showed that 70% of women with early stage breast cancer can skip chemotherapy and can be effectively treated with just hormone therapy.

Genomic makes a genetic test known as Oncotype DX Breast Recurrence Score, which helps in predicting the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

The study, dubbed TAILORx, included 10,273 women with breast cancer that grew in response to the hormone estrogen, tested negative for the HER2 gene and had not spread to the lymph nodes. Women who scored between zero and 10 on Genomic's test were treated with only hormone therapy, also known as endocrine therapy, and those who scored between 26 and 100, received both hormone therapy and chemotherapy.

Results from the study, presented at the annual meeting of the American Society of Clinical Oncology, showed that chemotherapy may be skipped in 70% of all women who are diagnosed with this types of breast cancer and score zero to 25 on the test, including patients over 50 years of age, and all women age 50 or younger with a test score of zero to 15.

In addition, the trial found that 30% of the patients, including women of any age with a score from 26 to 100, will see a benefit from chemotherapy. In women below 50, a 2% benefit from chemotherapy was observed with test scores of 16 to 20, and the benefit gradually grew as scores increased up to and above 25.

Genomic's shares were up 18.05% to $46.85 as of 2:18 p.m. ET on June 4.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.